Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Quebec Adds Momentum To Canadian Biosimilar Switching

Canadian Province Becomes Latest To Introduce Switching Program

Executive Summary

Quebec has become the latest Canadian province to introduce a biosimilar switching program, following in the footsteps of British Columbia, Alberta and New Brunswick.

You may also be interested in...



Biosimilars Canada Boss Calls For Ontario Switching Policy

Biosimilars Canada president Jim Keon has urged the province of Ontario to follow other Canadian provinces by adopting a biosimilar switching policy for its public drug program, in order to cut costs on biologics and re-invest in the healthcare system.

Fresenius Kabi Awaits EMA Inspection For Pegfilgrastim Biosimilar

Having recently announced plans to launch a further four biosimilar products in the next four years, Fresenius Kabi has disclosed the latest on its bid to introduce pegfilgrastim, which has been hamstrung in the US by delayed inspections.

Third Canadian Province Follows On Biosimilar Switching

New Brunswick has become the latest Canadian province to introduce a biosimilar switching program, with the newly-introduced scheme covering several biologic molecules.

Related Content

Topics

UsernamePublicRestriction

Register

GB150929

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel